Financial toxicity can have an impact on patients' anxiety and depression, but oncology nurses can help.
Financial burden affects many cancer survivors, making them more prone to experience depression or anxiety, according to Raymond Chan, PhD, RN, BN, MAppSc, professor of cancer nursing at Queensland University of Technology in Brisbane, Australia.
Since oncology nurses are often at the forefront of patient care, they are in a prime position to discuss financial toxicity with their patients and intervene, if needed.
The impact is huge. What we actually observe is that some patients can actually go to the extent of foregoing treatment. In this particular work that I am presenting this year at ONS Congress, is on the relationship around financial toxicity and symptom burden, and in particular, what we found is that there are at least 2 big studies, one in the 600s and the other one over 1,000, of cancer survivors. They reported that people who have experienced financial distress are 3 times more likely than people who have not, to experience depression and anxiety. So that in itself is a huge implication for oncology nurses and we are well placed to intervene.
Nursing Perspectives on Managing Toxicities With ADCs in Metastatic Gastric and Breast Cancers
September 1st 2022In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.
ERBT Before Ra-223 May Not Increase Hematological Toxicity in mCRPC
January 26th 2024Patients with metastatic castration-resistant prostate cancer who were previously treated with external beam radiation therapy before radium-223 did not experience an increase in hematological toxicity compared with the overall population.
Side Effect Education Critical for Patients With Cervical Cancer Treated With Pembrolizumab
January 22nd 2024With pembrolizumab plus chemoradiotherapy now approved by the FDA for patients with advanced cervical cancer, one expert explained the importance of “making sure that patients know what to look for and what to report.”